The event not only offers latest updates on Quality culture, Mergers & Acquisitions, enhancing Export avenues, Biosimilars & Make in India but also provides a platform to Network with MD’s, CxO’ and other decision makers.
With DR SUBIR BASAK, DR DHILEEP KRISHNAMURTHY, at Westin Hotel, Mumbai, India, Cphi India.....CPhI ‘s 2nd Pre Connect Congress 2016
Anita Ranjan Srivastava AT PRECONNECT CONGRESS
Mr. Andreas Mavrommatis; and Dr Ranjan srivastava
Global Marketing Director UBMCPhI India; Pre-Connect Congress 17th Nov 2016— Ranjan Srivastava.
VIRAL BHATT, UBM — with Viral Bhatt at The Westin Mumbai Garden City.
Conference Day One - 17th November 2016
Panel 1: Exploring conventional and unconventional avenues to enhance pharmaceutical export potential
Strategising to rise above overdependence on international markets for API sourcing
Analysing the recent government initiatives to promote pharmaceutical exports
Assessing the impact of pricing policy on the current export portfolios of Indian companies
Prashant Nagre, Chief Executive Officer, Fermenta Biotech
Panel 2: Mergers and Acquisition – Driving force for Indian Pharma sector
Recent trends & key drivers for M&A
Moving beyond traditional Mergers and Acquisition
Quantifying the impact of FDI implications on the growth of Indian pharma sector
Sudarshan Jain, Managing Director Healthcare Solutions, Abbott
Sanjay Singh, Partner, Deal Advisory M&A, KPMG India
Bhupender Saggu, Pharma Specialist, Thomson Reuters
Moderator:
Rakesh Bhargava, Chairman, Fresenius Kabi Oncology Ltd
Panel 3: Biosimilars – The next big thing
Expanding the biosimilars research ecosystem to accelerate capitalization on the patent cliff
Discussing the CDSCO guidance and its implication on the biosimilar market
Demystifying the regulatory pathway to ensure speedier approvals
Kanchana TK, Director General, OPPI
Panel 4: Quality Compliance – A cultural pre-requisite or external obligation
Overcoming the cultural sclerosis in the Indian industry to up the quality game
Improvising internal controls to reduce quality related corrective actions
Inculcating quality commitments in the pharmaceutical curriculum
CT. Renganathan, Managing Director, RPG Lifesciences
D G Shah, Secretary General, IPA
Sanjit Singh Lamba, Managing Director, Eisai Pharmaceuticals
Ashok Bhattacharya, Managing Director, Takeda Pharmaceuticals
Panel 5: Make in India – A Pharma Perspective
Transitioning from Generic to Innovative
Examining the investment opportunities and returns from initiative
Blending the role of FDI into the Make in India wave
H. G Koshia, Commissioner, Food & Drugs Control Administration, Gujarat
Mr. Amit Sanghvi, Managing Director, Shaily Engineering Plastics Limited
Panel 1: Exploring conventional and unconventional avenues to enhance pharmaceutical export potential
Strategising to rise above overdependence on international markets for API sourcing
Analysing the recent government initiatives to promote pharmaceutical exports
Assessing the impact of pricing policy on the current export portfolios of Indian companies
Prashant Nagre, Chief Executive Officer, Fermenta Biotech
Panel 2: Mergers and Acquisition – Driving force for Indian Pharma sector
Recent trends & key drivers for M&A
Moving beyond traditional Mergers and Acquisition
Quantifying the impact of FDI implications on the growth of Indian pharma sector
Sudarshan Jain, Managing Director Healthcare Solutions, Abbott
Sanjay Singh, Partner, Deal Advisory M&A, KPMG India
Bhupender Saggu, Pharma Specialist, Thomson Reuters
Moderator:
Rakesh Bhargava, Chairman, Fresenius Kabi Oncology Ltd
Panel 3: Biosimilars – The next big thing
Expanding the biosimilars research ecosystem to accelerate capitalization on the patent cliff
Discussing the CDSCO guidance and its implication on the biosimilar market
Demystifying the regulatory pathway to ensure speedier approvals
Kanchana TK, Director General, OPPI
Panel 4: Quality Compliance – A cultural pre-requisite or external obligation
Overcoming the cultural sclerosis in the Indian industry to up the quality game
Improvising internal controls to reduce quality related corrective actions
Inculcating quality commitments in the pharmaceutical curriculum
CT. Renganathan, Managing Director, RPG Lifesciences
D G Shah, Secretary General, IPA
Sanjit Singh Lamba, Managing Director, Eisai Pharmaceuticals
Ashok Bhattacharya, Managing Director, Takeda Pharmaceuticals
Panel 5: Make in India – A Pharma Perspective
Transitioning from Generic to Innovative
Examining the investment opportunities and returns from initiative
Blending the role of FDI into the Make in India wave
H. G Koshia, Commissioner, Food & Drugs Control Administration, Gujarat
Mr. Amit Sanghvi, Managing Director, Shaily Engineering Plastics Limited
The presentation will load below
